441798-25-0

Basic information

• Product Name: Macitentan impurity A
• Synonyms: Macitentan impurity A
• CAS NO: 441798-25-0
• Molecular Formula: C₁₇H₁₆Br₂N₆O₄S
• Molecular Weight: 560.21974
• EINECS: -0
• Mol File: 441798-25-0.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Macitentan impurity A(CAS DataBase Reference)
• NIST Chemistry Reference: Macitentan impurity A(441798-25-0)
• EPA Substance Registry System: Macitentan impurity A(441798-25-0)

Safety Data

• Hazardous Substances Data: 441798-25-0(Hazardous Substances Data)

Usage

Description

Macitentan impurity A, also known as N-Despropyl-N-methyl Macitentan, is an impurity found in Macitentan (M105005), a dual orally active and potent endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension.

Uses

Used in Pharmaceutical Industry:
Macitentan impurity A is used as a reference material for quality control and analytical testing in the pharmaceutical industry. It helps ensure the purity and safety of Macitentan, the active drug used for treating pulmonary arterial hypertension.

Upstream product

• 32779-36-5 5-Bromo-2-chloropyrimidine 
• 146533-41-7 5-(4-bromophenyl)-4,6-dichloropyrimidine 
• 706811-25-8 5-(4-bromophenyl)-4,6-dihydroxypyrimidine 
• 149506-35-4 2-(4-bromophenyl)-malonic acid dimethyl ester 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 

Relevant articles and documents

The discovery of N -[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy] ethoxy]-4-pyrimidinyl]- N ′-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist

Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy. This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines. Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ET B receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats. Compound 17 successfully completed a long-term phase III clinical trial for pulmonary arterial hypertension.